Tuberculosis

Madhukar Pai, Marcel A. Behr, David Dowdy, Keertan Dheda, Maziar Divangahi, Catharina C. Boehme, Ann Ginsberg, Soumya Swaminathan, Melvin Spigelman, Haileyesus Getahun, Dick Menzies, Mario Raviglione

Research output: Contribution to journalReview article

210 Citations (Scopus)

Abstract

Tuberculosis (TB) is an airborne infectious disease caused by organisms of the Mycobacterium tuberculosis complex. Although primarily a pulmonary pathogen, M. tuberculosis can cause disease in almost any part of the body. Infection with M. tuberculosis can evolve from containment in the host, in which the bacteria are isolated within granulomas (latent TB infection), to a contagious state, in which the patient will show symptoms that can include cough, fever, night sweats and weight loss. Only active pulmonary TB is contagious. In many low-income and middle-income countries, TB continues to be a major cause of morbidity and mortality, and drug-resistant TB is a major concern in many settings. Although several new TB diagnostics have been developed, including rapid molecular tests, there is a need for simpler point-of-care tests. Treatment usually requires a prolonged course of multiple antimicrobials, stimulating efforts to develop shorter drug regimens. Although the Bacillus Calmette-Guérin (BCG) vaccine is used worldwide, mainly to prevent life-threatening TB in infants and young children, it has been ineffective in controlling the global TB epidemic. Thus, efforts are underway to develop newer vaccines with improved efficacy. New tools as well as improved programme implementation and financing are necessary to end the global TB epidemic by 2035.

Original languageEnglish
Article number16076
JournalNature Reviews Disease Primers
Volume2
DOIs
Publication statusPublished - 27-10-2016

Fingerprint

Tuberculosis
Mycobacterium tuberculosis
Point-of-Care Systems
Latent Tuberculosis
BCG Vaccine
Multidrug-Resistant Tuberculosis
Sweat
Granuloma
Human Body
Pulmonary Tuberculosis
Cough
Bacillus
Communicable Diseases
Weight Loss
Fever
Vaccines
Morbidity
Bacteria
Lung
Mortality

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., ... Raviglione, M. (2016). Tuberculosis. Nature Reviews Disease Primers, 2, [16076]. https://doi.org/10.1038/nrdp.2016.76
Pai, Madhukar ; Behr, Marcel A. ; Dowdy, David ; Dheda, Keertan ; Divangahi, Maziar ; Boehme, Catharina C. ; Ginsberg, Ann ; Swaminathan, Soumya ; Spigelman, Melvin ; Getahun, Haileyesus ; Menzies, Dick ; Raviglione, Mario. / Tuberculosis. In: Nature Reviews Disease Primers. 2016 ; Vol. 2.
@article{f80214ffc1e241aba3f2e073e3112ced,
title = "Tuberculosis",
abstract = "Tuberculosis (TB) is an airborne infectious disease caused by organisms of the Mycobacterium tuberculosis complex. Although primarily a pulmonary pathogen, M. tuberculosis can cause disease in almost any part of the body. Infection with M. tuberculosis can evolve from containment in the host, in which the bacteria are isolated within granulomas (latent TB infection), to a contagious state, in which the patient will show symptoms that can include cough, fever, night sweats and weight loss. Only active pulmonary TB is contagious. In many low-income and middle-income countries, TB continues to be a major cause of morbidity and mortality, and drug-resistant TB is a major concern in many settings. Although several new TB diagnostics have been developed, including rapid molecular tests, there is a need for simpler point-of-care tests. Treatment usually requires a prolonged course of multiple antimicrobials, stimulating efforts to develop shorter drug regimens. Although the Bacillus Calmette-Gu{\'e}rin (BCG) vaccine is used worldwide, mainly to prevent life-threatening TB in infants and young children, it has been ineffective in controlling the global TB epidemic. Thus, efforts are underway to develop newer vaccines with improved efficacy. New tools as well as improved programme implementation and financing are necessary to end the global TB epidemic by 2035.",
author = "Madhukar Pai and Behr, {Marcel A.} and David Dowdy and Keertan Dheda and Maziar Divangahi and Boehme, {Catharina C.} and Ann Ginsberg and Soumya Swaminathan and Melvin Spigelman and Haileyesus Getahun and Dick Menzies and Mario Raviglione",
year = "2016",
month = "10",
day = "27",
doi = "10.1038/nrdp.2016.76",
language = "English",
volume = "2",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",

}

Pai, M, Behr, MA, Dowdy, D, Dheda, K, Divangahi, M, Boehme, CC, Ginsberg, A, Swaminathan, S, Spigelman, M, Getahun, H, Menzies, D & Raviglione, M 2016, 'Tuberculosis', Nature Reviews Disease Primers, vol. 2, 16076. https://doi.org/10.1038/nrdp.2016.76

Tuberculosis. / Pai, Madhukar; Behr, Marcel A.; Dowdy, David; Dheda, Keertan; Divangahi, Maziar; Boehme, Catharina C.; Ginsberg, Ann; Swaminathan, Soumya; Spigelman, Melvin; Getahun, Haileyesus; Menzies, Dick; Raviglione, Mario.

In: Nature Reviews Disease Primers, Vol. 2, 16076, 27.10.2016.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Tuberculosis

AU - Pai, Madhukar

AU - Behr, Marcel A.

AU - Dowdy, David

AU - Dheda, Keertan

AU - Divangahi, Maziar

AU - Boehme, Catharina C.

AU - Ginsberg, Ann

AU - Swaminathan, Soumya

AU - Spigelman, Melvin

AU - Getahun, Haileyesus

AU - Menzies, Dick

AU - Raviglione, Mario

PY - 2016/10/27

Y1 - 2016/10/27

N2 - Tuberculosis (TB) is an airborne infectious disease caused by organisms of the Mycobacterium tuberculosis complex. Although primarily a pulmonary pathogen, M. tuberculosis can cause disease in almost any part of the body. Infection with M. tuberculosis can evolve from containment in the host, in which the bacteria are isolated within granulomas (latent TB infection), to a contagious state, in which the patient will show symptoms that can include cough, fever, night sweats and weight loss. Only active pulmonary TB is contagious. In many low-income and middle-income countries, TB continues to be a major cause of morbidity and mortality, and drug-resistant TB is a major concern in many settings. Although several new TB diagnostics have been developed, including rapid molecular tests, there is a need for simpler point-of-care tests. Treatment usually requires a prolonged course of multiple antimicrobials, stimulating efforts to develop shorter drug regimens. Although the Bacillus Calmette-Guérin (BCG) vaccine is used worldwide, mainly to prevent life-threatening TB in infants and young children, it has been ineffective in controlling the global TB epidemic. Thus, efforts are underway to develop newer vaccines with improved efficacy. New tools as well as improved programme implementation and financing are necessary to end the global TB epidemic by 2035.

AB - Tuberculosis (TB) is an airborne infectious disease caused by organisms of the Mycobacterium tuberculosis complex. Although primarily a pulmonary pathogen, M. tuberculosis can cause disease in almost any part of the body. Infection with M. tuberculosis can evolve from containment in the host, in which the bacteria are isolated within granulomas (latent TB infection), to a contagious state, in which the patient will show symptoms that can include cough, fever, night sweats and weight loss. Only active pulmonary TB is contagious. In many low-income and middle-income countries, TB continues to be a major cause of morbidity and mortality, and drug-resistant TB is a major concern in many settings. Although several new TB diagnostics have been developed, including rapid molecular tests, there is a need for simpler point-of-care tests. Treatment usually requires a prolonged course of multiple antimicrobials, stimulating efforts to develop shorter drug regimens. Although the Bacillus Calmette-Guérin (BCG) vaccine is used worldwide, mainly to prevent life-threatening TB in infants and young children, it has been ineffective in controlling the global TB epidemic. Thus, efforts are underway to develop newer vaccines with improved efficacy. New tools as well as improved programme implementation and financing are necessary to end the global TB epidemic by 2035.

UR - http://www.scopus.com/inward/record.url?scp=84992597251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992597251&partnerID=8YFLogxK

U2 - 10.1038/nrdp.2016.76

DO - 10.1038/nrdp.2016.76

M3 - Review article

C2 - 27784885

AN - SCOPUS:84992597251

VL - 2

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

M1 - 16076

ER -

Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC et al. Tuberculosis. Nature Reviews Disease Primers. 2016 Oct 27;2. 16076. https://doi.org/10.1038/nrdp.2016.76